Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on NextCure (NXTC) to $15 from $36 and keeps an Overweight rating on the shares. The firm notes NextCure exercised a 12-for-1 reverse stock split effective July 14th. Piper estimates NextCure now has 2.338 million shares outstanding and trades at an $11.5M market cap.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXTC: